FDA delays Novo’s hemophilia A drug review over factory issues
US regulators have extended their review of Novo's hemophilia A injection, denecimig, because of issues at an unnamed manufacturing facility. The FDA attributed the delay to “ongoing facility remediation activities” observed during a pre-license inspection ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.